Cefaclor Extended-Release Tablets Rx
Generic Name and Formulations:
Cefaclor 375mg, 500mg; ext-rel tabs.
Various generic manufacturers
Indications for Cefaclor Extended-Release Tablets:
Susceptible mild to moderate infections including acute exacerbations of chronic bronchitis, secondary infections of acute bronchitis, pharyngitis/tonsillitis, uncomplicated skin and skin structures.
Take with meals. Swallow whole. Cefaclor ext-rel tab 500mg twice daily clinically equivalent to caps 250mg three times daily. ≥16yrs: Bronchitis: 500mg every 12 hrs for 7 days. Pharyngitis/tonsillitis: 375mg every 12 hrs for 10 days. Skin and skin structures: 375mg every 12 hrs for 7–10 days.
<16yrs: not recommended.
Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. ER: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.
Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.
Formerly known under the brand names Ceclor CD (ext-rel tabs); Ceclor (caps, susp); Raniclor (caps).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|